v3.26.1
Segment Reporting - Segment Information (Details)
$ in Thousands
 6 Months Ended
Jun. 30, 2026
USD ($)
item
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Segment reporting      
Number of Reportable Segments Not Disclosed [Flag] true    
Number of core business areas | item 2    
Revenue from external customers $ 278,287 $ 277,677  
Cost of revenue (152,158) (167,577)  
Research and development expenses (78,783) (71,990)  
Selling expenses (14,682) (13,873)  
Administrative expenses (31,795) (27,751)  
Gain on divestment of an equity investee   477,456  
Interest income 26,542 19,589  
Interest expense (1,425) (1,465)  
Equity in earnings of equity investees, net of tax 3,798 23,125  
Income tax expense (1,209) (63,162)  
Other segment items (12,647) 2,925  
Net income attributable to the Company 15,928 454,954  
Depreciation/amortization (7,072) (6,118)  
Impairment (note) (8,941)    
Additions to non-current assets (other than financial instruments and deferred tax assets) 7,025 15,799  
Segment information      
Total assets 1,736,427   $ 1,753,097
Property, plant and equipment 93,788   94,623
Right-of-use assets 7,330   3,027
Leasehold land 11,313   10,954
Intangible asset     8,941
Goodwill 3,234   3,112
Investment in equity investees 11,020   10,865
Oncology/Immunology segment      
Segment reporting      
Revenue from external customers 162,321 143,447  
Other Ventures segment      
Segment reporting      
Revenue from external customers 115,966 134,230  
Reportable segment | Oncology/Immunology segment      
Segment reporting      
Revenue from external customers 162,321 143,447  
Cost of revenue (40,350) (38,223)  
Research and development expenses (78,783) (71,990)  
Selling expenses (12,709) (11,828)  
Administrative expenses (19,096) (16,163)  
Interest income 309 509  
Interest expense (1,049) (1,033)  
Equity in earnings of equity investees, net of tax 11    
Income tax expense (802) (461)  
Other segment items (10,984) (2,686)  
Net income attributable to the Company (1,132) 1,572  
Depreciation/amortization (6,998) (6,024)  
Impairment (note) (8,941)    
Additions to non-current assets (other than financial instruments and deferred tax assets) 6,780 15,649  
Segment information      
Total assets 270,174   266,731
Property, plant and equipment 93,382   94,194
Right-of-use assets 6,159   1,451
Leasehold land 11,313   10,954
Intangible asset     8,941
Investment in equity investees 4,446   5,725
Reportable segment | Oncology/Immunology segment | R&D      
Segment reporting      
Revenue from external customers 40,887 44,408  
Research and development expenses (78,783) (71,990)  
Administrative expenses (16,910) (14,599)  
Interest income 309 509  
Interest expense (1,049) (1,033)  
Equity in earnings of equity investees, net of tax 11    
Income tax expense (337) (394)  
Other segment items (1,531) (2,612)  
Net income attributable to the Company (57,403) (45,711)  
Depreciation/amortization (4,849) (5,602)  
Additions to non-current assets (other than financial instruments and deferred tax assets) 6,774 5,649  
Segment information      
Total assets 182,720   175,378
Property, plant and equipment 93,382   94,194
Right-of-use assets 6,159   1,451
Leasehold land 11,313   10,954
Investment in equity investees 4,446   5,725
Reportable segment | Oncology/Immunology segment | Marketed Products      
Segment reporting      
Revenue from external customers 121,434 99,039  
Cost of revenue (40,350) (38,223)  
Selling expenses (12,709) (11,828)  
Administrative expenses (2,186) (1,564)  
Income tax expense (465) (67)  
Other segment items (9,453) (74)  
Net income attributable to the Company 56,271 47,283  
Depreciation/amortization (2,149) (422)  
Impairment (note) (8,941)    
Additions to non-current assets (other than financial instruments and deferred tax assets) 6 10,000  
Segment information      
Total assets 87,454   91,353
Intangible asset     8,941
Reportable segment | Other Ventures segment      
Segment reporting      
Revenue from external customers 115,966 134,230  
Cost of revenue (111,808) (129,354)  
Selling expenses (1,973) (2,045)  
Administrative expenses (2,327) (2,222)  
Interest income 32 57  
Interest expense (210) (257)  
Equity in earnings of equity investees, net of tax 3,787 23,125  
Income tax expense (27) (481)  
Other segment items 396 928  
Net income attributable to the Company 3,836 23,981  
Depreciation/amortization (53) (51)  
Additions to non-current assets (other than financial instruments and deferred tax assets) 242 150  
Segment information      
Total assets 148,795   117,359
Property, plant and equipment 367   370
Right-of-use assets 726   918
Goodwill 3,234   3,112
Investment in equity investees 6,574   5,140
Unallocated      
Segment reporting      
Administrative expenses (10,372) (9,366)  
Gain on divestment of an equity investee   477,456  
Interest income 26,201 19,023  
Interest expense (166) (175)  
Income tax expense (380) (62,220)  
Other segment items (2,059) 4,683  
Net income attributable to the Company 13,224 429,401  
Depreciation/amortization (21) $ (43)  
Additions to non-current assets (other than financial instruments and deferred tax assets) 3    
Segment information      
Total assets 1,317,458   1,369,007
Property, plant and equipment 39   59
Right-of-use assets $ 445   $ 658